AstraZeneca plc: Why $4.20 Is The Magic Number

AstraZeneca plc’s (LON: AZN) management will be keeping a keen eye on the company’s earnings.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Executive compensation plans have always drawn shareholders criticism but AstraZeneca’s (LSE: AZN) (NYSE: AZN.US) ‘Azip’ plan has been designed with shareholders in mind. 

Azip was put together in order to safeguard Astra’s dividend payout to investors, as well as encouraging the company’s management to grow the payout at a sustainable rate and grow earnings per share.  

The criteria are simple. In order for the Azip plan to remain in effect, the dividend must not be cut and earnings per share must not fall below 1.5 times the dividend. If either of these targets are not met, then benefits are forfeited. Astra’s CEO, Pascal Soriot, stands to lose a bonus of 89,960 shares, roughly £4.1m worth of stock if the company fails to maintain these standards. 

 So, there’s a lot at stake but why is $4.20 such an important number?

The magic number 

The Azip plan states that Astra’s dividend must be covered one-and-a-half times by earnings per share. For the last three years Astra has paid out a dividend per share of $2.80. Multiply $2.80 by 1.5 and you get $4.20. 

What’s more, as part of the Azip plan, Astra cannot cut the dividend. With this being the case, the payout cannot be lowered in order to maintain cover of one-and-a-half times.

So overall, Astra’s earnings per share must stay above the key $4.20 level. At this level the payout is covered one-and-a-half times and rewards promised under the Azip plan are safe. However, if Astra cuts its dividend to save cash, or the company’s earnings per share fall below $4.20, then awards promised under the Azip plan are forfeit. 

Full steam ahead

Unfortunately, Astra’s management are running out of time to ensure that they meet the Azip criteria. Indeed, as Astra struggles with falling sales of its key products, earnings have been falling over the past five years. Full-year 2013 earnings per share were $5.05, down from $7.28 as reported for full-year 2011.

Moreover, within the group’s recently published third-quarter earnings announcement, management revealed that full-year 2014 earnings would be 15% lower than those reported for 2013, in part because of the stronger dollar. According to my figures, these forecasts suggest that Astra is set to report earnings per share of $4.29 for 2014, only just above the key $4.20 threshold. 

And with that key $4.20 threshold looming, Astra’s management have picked up the pace driving multiple deals through over the past month alone.

For example, since the beginning of October the company has revived the go-ahead from regulators for the development of several new, key drugs. An asset swap with peer Almirall has also been completed and Astra’s global biologics research and development arm, MedImmune, has entered into an agreement to acquire Definiens, a world-leading medical data analysis technology firm. 

Astra’s management knows that they stand to lose a lot if the dividend payout comes under pressure, so they’re working hard to ensure that the company returns to growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is another stock market crash on the way?

The US stock market has already crashed in 2022, losing 25% of its value at its June low. However, UK…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A 6.2% FTSE 100 dividend stock I’d buy to boost my income

This FTSE 100 dividend stock offers a yield well above the index average. Here's why I'd buy it to supercharge…

Read more »

Abstract 3d arrows with rocket
Investing Articles

2 beaten down FTSE 100 shares that look ready for liftoff 

With the UK market showing strong signs of recovery, I am considering these two overlooked FTSE 100 shares for my…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

3 top UK shares for August 2022 and beyond

I've been buying top UK shares since late June such as these three companies that look attractive right now.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

FTSE 100 live: the Footsie closes on 7,500

The Footsie, like many other global markets, has been pretty volatile in recent months, but today it almost closed above…

Read more »

Woman using laptop and working from home
Investing Articles

High-dividend stocks! Should I buy Royal Mail’s shares for its 7.3% yield?

The Royal Mail share price carries a dividend yield twice as large as the average for UK shares. Does this…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

UK shares: should I buy this oil and gas infrastructure stock?

Jabran Khan is looking for the best UK shares for his holdings. Could this oil and gas infrastructure provider fit…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

This REIT could be the perfect stock to supercharge my passive income stream!

Jabran Khan is looking for stocks to boost his passive income through dividend payments. He identifies one REIT to help…

Read more »